Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Lung Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1SCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Diseases 1High Grade Serous Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 58Cisplatin 32Oxaliplatin 28Fluorouracil 21lenvatinib 19durvalumab 18Capecitabine 17Leucovorin 15tislelizumab 10pembrolizumab 10apatinib 9Floxuridine 8Specimen Handling 7Panitumumab 7Magnetic Resonance Spectroscopy 7Albumin-Bound Paclitaxel 7sintilimab 6pemigatinib 6Radiotherapy 6Irinotecan 6Drug Therapy 6Biopsy 6tremelimumab 5regorafenib 5olaparib 5camrelizumab 5Taxes 5S 1 (combination) 5Nivolumab 5Folfox protocol 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cholangiocarcinoma × ceralasertib × Clear all
NCT03878095 2026-06-01

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
24 enrolled 12 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡